You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Bulk Pharmaceutical API Sources for ANADROL-50


✉ Email this page to a colleague

« Back to Dashboard


Bulk Pharmaceutical API Sources for ANADROL-50

Vendor Vendor Homepage Vendor Sku API Url
AKos Consulting & Solutions ⤷  Get Started Free AKOS027473312 ⤷  Get Started Free
LGC Standards ⤷  Get Started Free LGCFOR1287.00 ⤷  Get Started Free
LGC Standards ⤷  Get Started Free MM1287.00 ⤷  Get Started Free
Key Organics/BIONET ⤷  Get Started Free NS-05498 ⤷  Get Started Free
001Chemical ⤷  Get Started Free DY10766 ⤷  Get Started Free
LGC Standards ⤷  Get Started Free DRE-C15805500 ⤷  Get Started Free
AbMole Bioscience ⤷  Get Started Free M2910 ⤷  Get Started Free
>Vendor >Vendor Homepage >Vendor Sku >API Url

Bulk Active Pharmaceutical Ingredient (API) Sources for Anadrol-50: Market Overview and Strategic Insights

Last updated: July 30, 2025

Introduction

Anadrol-50, scientifically known as Oxymetholone, is a potent oral anabolic steroid primarily used in clinical settings for treating anemia and muscle-wasting conditions. Its popularity has extended into the fitness and bodybuilding sectors, where it is prized for its ability to promote significant muscle mass gains. As demand grows, sourcing high-quality API becomes critical for pharmaceutical manufacturers, compounding pharmacies, and illicit markets alike. This article examines the landscape of API sourcing for Anadrol-50, considering regulatory frameworks, key global suppliers, quality assurance practices, and market dynamics shaping API procurement.


Regulatory Landscape Impacting API Sourcing

The procurement of Anadrol-50 API is heavily influenced by international and regional regulatory environments. In the United States, the Drug Enforcement Administration (DEA) tightly controls Oxymetholone under the Controlled Substances Act, classifying it as a Schedule III substance. Consequently, legal importation and manufacturing are restricted to licensed entities with stringent compliance obligations. Conversely, in countries like India, China, and certain European nations, regulatory oversight varies, affecting API manufacturing capabilities, export licenses, and quality standards.

The global trend toward stricter Good Manufacturing Practice (GMP) compliance has prompted suppliers to adopt higher standards, impacting sourcing options. Manufacturers must verify that suppliers adhere to worldwide quality standards, particularly those aligning with USP (United States Pharmacopeia) or EP (European Pharmacopoeia) specifications.


Major API Manufacturers for Anadrol-50

The supply chain for Anadrol-50 API is characterized by a mix of licensed pharmaceutical manufacturers, reputed research-based API producers, and, in some cases, illegitimate sources. The most prominent legal API producers include:

  • Hetero Labs (India): One of the leading global API producers, Hetero has a diverse portfolio that includes anabolic steroids under strict quality controls. Their API manufacturing processes comply with international GMP standards, making them a preferred partner for pharmaceutical companies seeking reliable product sources.

  • Jiangsu Hengrui Medicine Co., Ltd. (China): Recognized for its extensive portfolio of active ingredients, this firm supplies pharmaceutical-grade Oxymetholone for both domestic and international markets, adhering to rigorous quality standards.

  • Dongying Pharmaceutical Co., Ltd. (China): Established in the production of steroid APIs, Dongying offers Oxymetholone APIs often used in controlled pharmaceutical manufacturing.

  • Wor-Wic Industries (India): Although primarily a research-focused entity, they occasionally supply API batches suitable for pharmaceutical development under licensing agreements.

Additionally, many established pharmaceutical API manufacturers in Europe and North America may produce Anadrol-50 under strict licensing, but their products are often limited to pharmaceutical companies with verified manufacturing licenses due to regulatory constraints.


Sources and Quality Assurance

Securing Anadrol-50 API demands cross-verification of supplier credentials, batch certificated documents, and third-party laboratory testing results. Key aspects include:

  • GMP Certification: Ensures the API has been produced under quality standards suitable for pharmaceutical use.

  • Certificate of Analysis (CoA): Critical for validating API purity, potency, and compliance with pharmacopoeial standards. Typical specifications include >98% purity and absence of contaminants like heavy metals or residual solvents.

  • Priorizen & Authenticity Verification: Engaging with suppliers with transparent supply chains and robust traceability mechanisms mitigates risks related to counterfeit or substandard API.

Given the global prevalence of counterfeit pharmaceuticals, buyers often rely on independent testing labs (e.g., Eurofins, Covance) for batch verification before procurement.


Market Dynamics Influencing API Supply

The API market for Anadrol-50 is affected by several macro and microeconomic factors:

  • Regulatory Restrictions: Increasing international controls on controlled substances restrict supply channels and elevate compliance costs, potentially reducing the number of available suppliers.

  • Manufacturing Capacity Constraints: The complexity of steroid API synthesis, coupled with high regulatory hurdles, limits the number of compliant manufacturing facilities, leading to potential shortages or price volatility.

  • Demand from Pharmaceutical and Illicit Markets: While legitimate pharmaceutical supply remains stable with high standards, illicit markets often source API from less regulated suppliers, risking quality, safety, and legal repercussions.

  • Trade Policies: Tariffs, export bans, and import restrictions impact global API supply chains, especially affecting suppliers in geopolitically sensitive regions.


Risks and Considerations in API Sourcing

Sourcing Anadrol-50 API, especially from unverified sources, presents numerous risks:

  • Counterfeit API: Fake or adulterated products jeopardize safety and efficacy, damaging reputation and incurring legal liability.

  • Regulatory Non-Compliance: Using non-GMP API can result in product recalls or legal sanctions, particularly in regulated markets like the US, EU, and Japan.

  • Price Volatility: Limited supplier pools and regulatory barriers contribute to fluctuations in API pricing.

  • Legal Risks: Illicit procurement or distribution of Anadrol-50 API can result in severe legal penalties, especially under drug control laws.

Due Diligence Strategies

To mitigate these risks, buyers should:

  • Prioritize suppliers with GMP certification and transparent documentation.

  • Conduct regular supplier audits and third-party testing.

  • Engage in long-term relationships with established API producers.

  • Stay compliant with regional import/export regulations.


Future Outlook and Innovation in API Sourcing

Emerging trends include the expansion of chemical synthesis techniques that could streamline Anadrol-50 API production, potentially reducing costs and regulatory hurdles. Suppliers investing in green chemistry and sustainable manufacturing are gaining favor, aligning with global sustainability standards.

Advances in digital supply chain management and blockchain technology offer enhanced transparency and traceability, facilitating secure API sourcing.

Furthermore, regional shifts in manufacturing capacity—such as India and China increasing GMP-certified facilities—may result in diversified, more resilient supply chains.


Key Takeaways

  • Regulatory compliance is paramount; sourcing API from GMP-certified, licensed manufacturers ensures quality and legal adherence.

  • Leading API producers include companies like Hetero Labs and Jiangsu Hengrui, with established reputations for quality.

  • Due diligence involving third-party testing and certification safeguards against counterfeit or substandard API.

  • Market dynamics, through regulatory restrictions and geopolitical factors, influence API availability, pricing, and supply stability.

  • Future trends emphasize sustainability, supply chain transparency, and technological innovation to enhance sourcing security.


FAQs

1. Is Anadrol-50 API readily available from licensed suppliers globally?
Availability varies by region due to stringent regulatory controls. While licensed GMP-certified suppliers in India, China, and Europe can provide pharmaceutical-grade Anadrol-50 API, procurement requires compliance with local laws, licensing, and verification procedures.

2. What factors determine the quality of Anadrol-50 API from different suppliers?
Quality hinges on GMP certification, purity levels (>98%), comprehensive certificate of analysis, and traceability. Suppliers adhering to recognized pharmacopeial standards and conducting independent testing ensure a higher quality product.

3. Are there risks involved in sourcing Anadrol-50 API online from unverified sources?
Yes. Unverified sources may supply counterfeit, contaminated, or adulterated API, posing safety risks and potential legal liabilities. Always verify supplier credentials and seek third-party testing.

4. How do regulatory changes impact the global supply of Anadrol-50 API?
Tighter controls and international drug laws restrict production and export, reducing available sources and increasing prices. Staying informed of regional regulations is essential for procurement strategies.

5. What are the future prospects for API sourcing in the Anadrol-50 market?
Emerging manufacturing technologies, stricter quality standards, and increased regional production capacities are expected to improve API stability, reduce costs, and enhance supply resilience.


References

[1] U.S. Drug Enforcement Agency. (2023). Controlled Substances Act Schedule.
[2] Hetero Labs. (2023). API Portfolio Specifications.
[3] Jiangsu Hengrui Medicine Co., Ltd. Reports.
[4] European Pharmacopoeia. (2022). Standard Specifications for Active Ingredients.
[5] Market research reports on pharmaceutical APIs and anabolic steroids industry.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.